Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials

Annals of Oncology 2026

View at publisher
Authors: S.-D. Hong, Y.-S. Wang, H.-Y. Zhao, Y.-Y. Zhao, Q.-M. Wang, Y.-X. Ma, Y.-S. Li, Y. Huang, Y.-P. Yang, Z.-M. Fu, L.-K. Chen, F. Zhou
+26 more J. Yang, X.-Y. Li, X. Hou, N.-N. Zhou, L.-H. Sun, G.-F. Zhang, J.-W. Cui, L. Wu, G. R. Chen, Y.-X. Zhang, H.-Y. Wang, D.-Q. Lv, J.-H. Shi, B. Jiang, C. Li, X.-L. Li, K.-J. Tang, Y. M. Yu, Y.-H. Ji, Z.-Y. He, Y. Zhu, H. Zhu, S. Xiao, C.-C. Zhou, L. Zhang, W.-F. Fang
DOI: 10.1016/j.annonc.2026.01.009
Cited by: 11
References: 41

Fields of Study & Subjects

HER2/EGFR in Cancer Research Lung Cancer Treatments and Mutations Colorectal Cancer Treatments and Studies

Publication details

Journal / source
Annals of Oncology
Publisher
Elsevier BV
Volume
37
Issue
6
Pages
813–824
Publication date
27 January 2026
Language
EN